Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917679 | 0.84 | MAPT (0.66) | MAPTHPGDKDM4EL3MBTL1RAB9A | |
| SCHEMBL4244499 | 0.77 | RAB9A (0.40) | MAPTHPGDKDM4ERAB9AHTT | |
| SCHEMBL1886219 | 0.67 | KMT2A (0.52) | MAPTHPGDKDM4ERAB9AHTT | |
| SCHEMBL1918939 | 0.66 | NPC1 (0.57) | MAPTHPGDKDM4ERAB9AHTT | |
| SCHEMBL4738752 | 0.66 | RAB9A (0.69) | MAPTHPGDRAB9AHTTSMN1; SMN2 | |
| SCHEMBL844402 | 0.65 | DAO (0.59) | MAPTHPGDKDM4EL3MBTL1RAB9A | |
| SCHEMBL1918608 | 0.65 | RAB9A (0.52) | MAPTHPGDKDM4EL3MBTL1RAB9A | |
| SCHEMBL4245262 | 0.65 | RAB9A (0.56) | MAPTRAB9AHTTP2RX1SMN1; SMN2 | |
| SCHEMBL1917598 | 0.64 | RAB9A (0.55) | MAPTHPGDKDM4ERAB9AHTT | |
| SCHEMBL8392815 | 0.63 | MEN1 (0.55) | MAPTHPGDKDM4ERAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2335702-A1 | Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent | IPSEN PHARMA (FR) | 2011-06-22 | — | — | EP | disclosed |
| EP-1641453-B1 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | IPSEN PHARMA (FR) | 2009-08-19 | — | — | EP | disclosed |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-28 | — | — | US | disclosed |
| US-7335674-B2 | Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS (S.C.R.A.S.) (FR) | 2008-02-26 | — | — | US | disclosed |
| EP-1792905-A1 | Product containing at least one phosphatase CDC25 inhibitor combined with at least one other anticancer agent | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2007-06-06 | — | — | EP | disclosed |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-12-14 | — | — | US | disclosed |
| US-20060135573-A1 | Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof | IPSEN PHARMA S.A.S. (FR) | 2006-06-22 | — | — | US | disclosed |
| EP-1641453-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641789-A2 | BENZOTHIAZOLE-4,7-DIONES AND BENZOXAZOLE-4,7-DIONES WITH SUBSTITUENTS IN POSITION 5 OR 6 AND METHOD FOR PRODUCTION THEREOF | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000843-A2 | BENZOTHIAZOLE-4,7-DIONES AND BENZOXAZOLE-4,7-DIONES WITH SUBSTITUENTS IN POSITION 5 OR 6 AND METHOD FOR PRODUCTION THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000852-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135573-A1 | Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof | CDC25A, CDC25C, CDC25B | MAPT 4055/4885HPGD 1962/4885KDM4E 220/4885 |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | CDC25A, CDC25C, CDC25B | MAPT 2216/4885HPGD 2723/4885KDM4E 2266/4885 |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | CDC25A, CDC25C, CDC25B | MAPT 2536/4885HPGD 2732/4885KDM4E 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.